Update on the management of cardiogenic shock

Mann, Henry J.; Nolan, Paul E.

doi:10.1097/01.ccx.0000244122.62118.da

Cited by 36 publications

(15 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Acute myocardial infarction (AMI) is the leading cause of morbidity and mortality among all the cardiovascular pathologies including thrombotic stroke, embolic vascular occlusions, angina pectoris, peripheral vascular insufficiency, cardiac surgery, organ transplantation, and cardiogenic shock [1]. AMI is a circumstance characterized by two events: the ischemia and the reperfusion of the myocardium, leading to injury of the myocardium and loss of its function.…”

Section: Introductionmentioning

confidence: 99%

Acute oxygen-ozone administration to rats protects the heart from ischemia reperfusion infarct

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Acute oxygen-ozone administration to rats protects the heart from ischemia reperfusion infarct

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Während der kardiogene Schock herkömmlicherweise durch einen hohen systemvaskulären Widerstand gekennzeichnet ist [17], verstärkte eine ausgeprägte Vasodilatation bei den drei beschriebenen Patienten den kardiogenen Schockzustand. Die Genese der vasodilatorischen Schock- komponente kann aufgrund der klinischen Verläufe allein nicht sicher erhoben werden.…”

Section: Diskussionunclassified

Vasopressin als Reservevasopressor

et al. 2007

View full text Add to dashboard Cite

Vasodilatory shock is the most common form of shock in the critically ill patient. As a consequence of overwhelming and prolonged mediator production, vasodilatory shock can be the common final pathway of primary non-vasodilatory shock (e.g. cardiogenic or hypovolemic shock). A supplementary infusion of arginine vasopressin (AVP) showed beneficial effects on hemodynamics and potentially on the outcome in patients with vasodilatory shock due to sepsis or after major surgery. In this case series, successful administration of AVP in three surgical patients with primary cardiogenic shock forms is reported. The hemodynamic effects of AVP were comparable to those AVP-induced alterations described in septic shock and seem to be predominantly mediated by potent vasoconstriction and the facilitated reduction of higher, potentially toxic catecholamine doses. Thus, an AVP-induced decrease in heart rate and pulmonary arterial pressures may be particularly beneficial in patients with impaired cardiac function.

show abstract

“…Despite early vascularization, mortality rates due to cardiogenic shock remain >50% in most studies (35). According to the GUSTO-I trial, 30-day survivors of cardiogenic shock have a similar prognosis to in 1327 patients with decompensated heart failure.…”

Section: Evidence-based Inotrope Use In Different Cardiovascular Scenmentioning

confidence: 99%

Review and update on inotropes and vasopressors: Evidence-based use in cardiovascular diseases

Kalçık¹,

Gürsoy²

2015

Curr Res Cardiol

View full text Add to dashboard Cite

Patients in the intensive care unit frequently develop low-output syndromes due to cardiac dysfunction, myocardial injury and activation of inflammatory cascades. Pharmacological agents, including vasodilators, inotropes and vasopressors, are frequently used in the critical care setting for the management of unstable cardiac patients. These medications are used to elicit varying effects on vascular resistance, myocardial contractility and heart rate to achieve desired hemodynamic and clinical end points. Conventional inotropic agents appear to be useful in restoring hemodynamic parameters and improving peripheral organ perfusion, but they can increase short-term and long-term mortality in these patients. Novel inotropes may be promising in the management of cardiogenic shock patients without serious adverse effects. The present review summarizes the current knowledge about the pathophysiology and evidence-based use of conventional and novel inotropic agents in various clinical scenarios associated with cardiovascular diseases.

show abstract

Update on the management of cardiogenic shock

Cited by 36 publications

References 47 publications

Acute oxygen-ozone administration to rats protects the heart from ischemia reperfusion infarct

Acute oxygen-ozone administration to rats protects the heart from ischemia reperfusion infarct

Vasopressin als Reservevasopressor

Review and update on inotropes and vasopressors: Evidence-based use in cardiovascular diseases

Contact Info

Product

Resources

About